IQVIA Holdings Inc. $IQV Shares Purchased by Cornerstone Investment Partners LLC

Cornerstone Investment Partners LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 21.9% in the third quarter, Holdings Channel reports. The fund owned 344,103 shares of the medical research company’s stock after buying an additional 61,725 shares during the period. IQVIA accounts for approximately 2.7% of Cornerstone Investment Partners LLC’s investment portfolio, making the stock its 17th largest holding. Cornerstone Investment Partners LLC’s holdings in IQVIA were worth $65,359,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA in the second quarter valued at approximately $515,772,000. Norges Bank purchased a new stake in IQVIA in the 2nd quarter valued at $270,160,000. AQR Capital Management LLC increased its stake in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Laurel Wealth Advisors LLC raised its holdings in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares during the period. Finally, Nordea Investment Management AB boosted its position in shares of IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 3.0%

Shares of IQV opened at $177.01 on Thursday. The company’s 50-day simple moving average is $225.42 and its 200-day simple moving average is $209.47. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a market capitalization of $30.14 billion, a PE ratio of 22.52, a P/E/G ratio of 1.76 and a beta of 1.37.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IQV. Morgan Stanley set a $240.00 target price on shares of IQVIA in a research note on Wednesday. Barclays reduced their price target on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Finally, BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $238.20.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.